Our top pick for
Aptevo Therapeutics Inc is a biotechnology business based in the US. Aptevo Therapeutics shares (APVO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptevo Therapeutics employs 80 staff and has a trailing 12-month revenue of around USD$34.4 million.
|Latest market close||USD$42.98|
|52-week range||USD$2.9442 - USD$60|
|50-day moving average||USD$41.7065|
|200-day moving average||USD$16.0967|
|Wall St. target price||USD$65.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.762|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||18.83%|
|1 month (2020-12-18)||7.40%|
|3 months (2020-10-16)||515.76%|
|6 months (2020-07-17)||448.21%|
|1 year (2020-01-17)||6,220.59%|
|2 years (2019-01-18)||2,569.57%|
|3 years (2018-01-18)||1,186.83%|
|5 years (2016-01-15)||N/A|
|Revenue TTM||USD$34.4 million|
|Gross profit TTM||USD$-17,260,000|
|Return on assets TTM||-38.59%|
|Return on equity TTM||-316.98%|
|Market capitalisation||USD$155 million|
TTM: trailing 12 months
There are currently 276,692 Aptevo Therapeutics shares held short by investors – that's known as Aptevo Therapeutics's "short interest". This figure is 71% down from 955,431 last month.
There are a few different ways that this level of interest in shorting Aptevo Therapeutics shares can be evaluated.
Aptevo Therapeutics's "short interest ratio" (SIR) is the quantity of Aptevo Therapeutics shares currently shorted divided by the average quantity of Aptevo Therapeutics shares traded daily (recently around 337429.26829268). Aptevo Therapeutics's SIR currently stands at 0.82. In other words for every 100,000 Aptevo Therapeutics shares traded daily on the market, roughly 820 shares are currently held short.
However Aptevo Therapeutics's short interest can also be evaluated against the total number of Aptevo Therapeutics shares, or, against the total number of tradable Aptevo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aptevo Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Aptevo Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.0402% of the tradable shares (for every 100,000 tradable Aptevo Therapeutics shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aptevo Therapeutics.
Find out more about how you can short Aptevo Therapeutics stock.
We're not expecting Aptevo Therapeutics to pay a dividend over the next 12 months.
Aptevo Therapeutics's shares were split on a 1:14 basis on 27 March 2020. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptevo Therapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Aptevo Therapeutics shares which in turn could have impacted Aptevo Therapeutics's share price.
Over the last 12 months, Aptevo Therapeutics's shares have ranged in value from as little as $2.9442 up to $60. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptevo Therapeutics's is 7.5766. This would suggest that Aptevo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.